# Soley Therapeutics

> Soley Therapeutics is a South San Francisco biotechnology company founded in 2020 by UCSF scientists Yerem Yeghiazarians and Kurosh Ameri. Its proprietary cell stress sensing platform combines live-cell imaging, automation and AI to discover internally developed drug candidates, beginning with oncology and extending into neurodegenerative and metabolic diseases. A $200 million Series C announced in January 2026 funds clinical preparation, trials and platform expansion.

- **Founded:** 2020
- **Headquarters:** South San Francisco, United States
- **Founders:** Yerem Yeghiazarians (Co-founder and Chief Executive Officer), Kurosh Ameri (Co-founder and Chief Scientific Officer)
- **Products:** Cell stress sensing platform, SoleyMap, SOL-001, STX-6398, Stress reversal discovery programs
- **Notable:** Announced a USD 200 million Series C on January 7, 2026., Peer-reviewed Live Cell Dynamics study published in Scientific Reports in January 2026., Reported STX-6398 activity in a 300-tumor-cell-line panel and xenograft models at AACR 2026.

## Products & services

- **Cell stress sensing platform** — Proprietary in-house live-cell imaging, automation and AI platform that measures dose- and time-resolved cellular responses to compounds. A discovery engine for its own pipeline, rather than a publicly priced software service.
- **SoleyMap** — Compact structured signatures derived from image-based whole-cell information, used to compare compound responses and investigate mechanisms.
- **SOL-001** — Lead oncology program aimed at acute myeloid leukemia; the January 2026 financing announcement targeted an IND filing during 2026.
- **STX-6398** — Investigational oral small-molecule modulator of CKAP2-associated pathways. Reported preclinical cancer activity at AACR 2026; public sources reviewed do not establish its correspondence to SOL-numbered assets.
- **Stress reversal discovery programs** — Early programs in neurodegenerative disease, obesity/metabolic disease and hair regeneration, intended to restore healthier cellular states.

## Achievements

- Announced a USD 200 million Series C on January 7, 2026.
- Peer-reviewed Live Cell Dynamics study published in Scientific Reports in January 2026.
- Reported STX-6398 activity in a 300-tumor-cell-line panel and xenograft models at AACR 2026.
- Company reports more than a dozen proprietary chemical series generated in under three years.
- Company platform page reports capacity to screen 100,000+ compounds per week.

## Latest updates

- **2026-09** — Company WordPress public news API lists a September 29 Technology Networks item titled Better Data, Not Just More Data: Moving Beyond Endpoints and Into Cells for Drug Discovery.
- **2026-07** — Company news API lists a July 29 Drug Discovery News item titled What Cells Can Teach Us About Discovering Better Drugs.
- **2026-06** — Appointed Berthil Clasen as Chief Business Officer to lead corporate strategy, business development and partnerships.
- **2026-04** — Announced AACR 2026 preclinical findings for STX-6398.
- **2026-01** — Announced Series C financing and publication of the Live Cell Dynamics study.

## Links

- Website: https://soleytherapeutics.com/
- LinkedIn: https://www.linkedin.com/company/soley-therapeutics/

---

Profile page: https://yespress.io/soley-therapeutics
Published by YesPress — https://yespress.io
Last updated: 2026-09-30